Research Summary

I am a medical oncologist with a PhD in cell and molecular biology. I maintain an active academic clinical practice and lead a basic and translational research laboratory focused on cancer genetics, precision medicine, and the molecular basis of targeted therapy response and resistance. I have discovered several mechanisms of resistance to EGFR-targeted therapy, BRAF- and MEK-targeted therapy, and ALK-targeted therapy in lung and other cancers. I direct a multi-disciplinary team engaged in laboratory-based patient-focused research, and I am an investigator on clinical trials, including rational upfront polytherapy trials designed to forestall and eliminate resistance and that are motivated by my laboratory-based discoveries.

Research Funding

  • July 1, 2019 - June 30, 2024 - (PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA231300
  • February 1, 2013 - January 31, 2024 - Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA169338
  • September 30, 2017 - August 31, 2022 - Bay Area Team Against Resistance, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: U54CA224081
  • August 10, 2017 - July 31, 2022 - The Cancer Target Discovery and Development Network at UCSF, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: U01CA217882


Vanderbilt University, B.S., 1998, Molecular Biology
New York University, School of Medicine, Ph.D., 2004, Cell and Mol. Biology
New York University, School of Medicine, M.D., 2005, Medicine
Brigham and Women’s Hospital/Harvard, 2005-2007, Internal Medicine
Memorial Sloan-Kettering Cancer Center, 2007-2011, Medical Oncology

Honors & Awards

  • 1998
    Vanderbilt University Honors Degree in Molecular Biology
  • 1998
    Vanderbilt University Research Excellence Award
  • 1998-2005
    NIH Medical Scientist Training Program Award
  • 2005
    Medical Science Writing Award, NYU School of Medicine
  • 2007
    US Patent 20060083742 Prenyl-electrostatic Switch
  • 2008-2010
    Charles A. Dana Foundation Clinical Scholars Research Fellowship
  • 2009
    Julia Zelmanovich Young Alumnus Award, NYU School of Medicine
  • 2010
    American Society of Clinical Oncology Young Investigator Award
  • 2010
    Uniting Against Lung Cancer Research Investigator
  • 2011
    NIH/NCI Clinical Investigator Career Development Award (K08)
  • 2012
    National Lung Cancer Partnership Young Investigator Award
  • 2012
    Sidney Kimmel Foundation Kimmel Scholar Award
  • 2012
    Damon Runyon Clinical Investigator Award Finalist
  • 2012
    Doris Duke Clinical Scientist Development Award
  • 2012
    American Lung Association Lung Cancer Discovery Award
  • 2012
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2012
    Visiting Scholar Howard Hughes Medical Institute (HHMI) Scholars Program at California, State University-Fullerton
  • 2012
    NIH Director's New Innovator Award (DP2)
  • 2013
    Searle Scholar Award
  • 2014
    Lung Cancer Innovators Award (Addario and Van Auken Foundations)
  • 2015
    Pew-Stewart Scholar, Pew Charitable Trust

Selected Publications

  1. Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.  View on PubMed
  2. Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.  View on PubMed
  3. Kerr DL, Haderk F, Bivona TG Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.  View on PubMed
  4. Nothdurft S, Thumser-Henner C, Breitenbücher F, Okimoto RA, Dorsch M, Opitz CA, Sadik A, Esser C, Hölzel M, Asthana S, Forster J, Beisser D, Kalmbach S, Grüner BM, Bivona TG, Schramm A, Schuler M Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis.  View on PubMed
  5. Liu J, Mayekar MK, Wu W, Yan M, Guan H, Wang J, Zaman A, Cui Y, Bivona TG, Choudhry H, Xing Q, Cao W Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G.  View on PubMed
  6. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.  View on PubMed
  7. Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, Schenk G, Shain AH, Biddle FG, Collisson E, Snyder M, Bivona TG Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.  View on PubMed
  8. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.  View on PubMed
  9. Bivona TG EGFR targeted therapy resistance: current status, challenges, and future outlook.  View on PubMed
  10. Fan Q, An Z, Wong RA, Luo X, Lu ED, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA Betacellulin drives therapy resistance in glioblastoma.  View on PubMed
  11. Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, Røsland GV, Siraji MI, Hellesøy M, Rayford A, Jacobsen K, Ditzel HJ, Vintermyr OK, Bivona TG, Minna J, Brekken RA, Baguley B, Micklem D, Akslen LA, Gausdal G, Simonsen A, Thiery JP, Chouaib S, Lorens JB, Engelsen AST AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.  View on PubMed
  12. Zargar A, Chang S, Kothari A, Snijders AM, Mao JH, Wang J, Hernández AC, Keasling JD, Bivona TG Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy.  View on PubMed
  13. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.  View on PubMed
  14. Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, Rosell R BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.  View on PubMed
  15. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.  View on PubMed
  16. Zaman A, Wu W, Bivona TG Targeting Oncogenic BRAF: Past, Present, and Future.  View on PubMed
  17. Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.  View on PubMed
  18. McCoach CE, Bivona TG Engineering Multidimensional Evolutionary Forces to Combat Cancer.  View on PubMed
  19. Bivona TG Dampening oncogenic RAS signaling.  View on PubMed
  20. Halliday PR, Blakely CM, Bivona TG Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI